Lexaria Bioscience Corp 2026年季度报告

FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedNovember 30, 2025 or For the transition period from[]to [] Commission file number001-39874 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Registrant’s Telephone number, including area code:1.250.765.6424 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports)and (2) has been subject to such filing requirements for the last 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated Filer If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date. 24,887,446common shares issuedas of January 13, 2026 TABLE OF CONTENTS PART I—FINANCIAL INFORMATION3Item 1. Financial Statements3Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item 3. Controls and Procedures.28PART II—OTHER INFORMATION29Item 1. Legal Proceedings29Item 1A. Risk Factors29Item 2. Recent Sales of Unregistered Equity Securities29Item 3. 10b5-1 Trading Plans29Item 4. Exhibits, Financial Statement Schedules29 Table of Contents PART I—FINANCIAL INFORMATION LEXARIA BIOSCIENCE CORP.CONSOLIDATED BALANCE SHEETS(Expressed in US Dollars)(Unaudited) LEXARIA BIOSCIENCE CORP.CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Expressed in US Dollars except share amounts)(Unaudited) LEXARIA BIOSCIENCE CORP.CONSOLIDATED STATEMENTS OF CASH FLOWS(Expressed in US Dollars)(Unaudited) LEXARIA BIOSCIENCE CORP.NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTSNovember 30, 2025(Expressed in U.S. Dollars Except Share Amounts)(Unaudited) 1. Nature of Business Lexaria Bioscience Corp. (“Lexaria”, “we”, “our” or “the Company”) is a biotechnology company pursuing the enhancement of thebioavailability of a diverse and broad range of active pharmaceutical ingredients (“API”) using our proprietary DehydraTECH drugdelivery technology.Our current focus is the investigation of the incorporation of our DehydraTECH drug delivery technology withGLP-1 and GIP drugs to reduce adverse events of these drugs while maintaining or enhancing their effectiveness. Revenues are generated from licensing contracts for the Company’s patented DehydraTECH technology based on the terms of use anddefinedgeographic and licensing arrangements.We derive income from our third party contracted manufacturing of B2BDehydraTECH enhanced products made to customer specifications that are sold online and in-store in the US and Canada. We alsoperform contract services in R&D for customer specific formulations that are used in comparison testing to customers’ existingproducts. Going Concern The Company’s consolidated financial statements included herein have been prepared pursuant to the rules and regulations of theSecurities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States(“US GAAP”) applicable to a going concern, which assumes the Company will have sufficient funds to meet its financial obligationsfor a period of at least 12 months from the date of this report. Since inception, the Company has incurred significant operating and net losses. Net losses attributable to shareholders were $1.6million and $2.7 million for the three months ended November 30, 2025, and November 30, 2024, respectively. As of November 30,2025, we had an accumulated deficit of $65.1 million. We expect to continue to incur significant operational expenses and net losses inthe upcoming 12 months. Our net losses may fluctuate significantly from quarter to quarter and year to year, depe